Free weekly newsletter

Get the free weekly contract digest

The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Starget Pharma and Cancer Focus Fund Announce $5.1 Million Investment to Support Phase 1b Clinical Trial

Oct 23, 2024•over 1 year ago

Contract Type

partnership

ShreveportBiotechnology

Description

Starget Pharma and Cancer Focus Fund have announced a $5.1 million investment to support a Phase 1b clinical trial of Starget’s lead theranostic, DOTA-PTR-58. The trial will target tumors overexpressing somatostatin receptor type 3 (SSTR-3), including sarcomas, neuroendocrine tumors (NET), melanoma, and hepatocellular carcinomas.

Company Information

Company

Starget Pharma

Location

Shreveport, Louisiana, United States

About

Starget Pharma is a clinical stage company developing a pipeline of radioligand therapy programs generated using its proprietary Backbone Dynamics peptide platform that leverages backbone cyclic innovations and in-silico AI to rapidly design highly specific Smart Targeted Radioligands (STRs) that deliver focused radiation for the imaging and treatment of hard-to-treat cancers.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Starget Pharma's next move

Learn about Strategic plan

Agreement Insights

Based on industry data

Strategic partnership established

Partnership agreements typically involve technology integration and joint go-to-market strategies

Contract momentum indicator

Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months